Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,886 questions in 74 reviews · Skin
current versionsNo studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
UVA1 vs narrowband UVB Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
UVA1 vs narrowband UVB Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
UVA1 vs narrowband UVB Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
UVA1 vs narrowband UVB Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
UVA1 vs narrowband UVB Proportion of participants with adverse effects measured over 10 weeks · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | 1 study · 33 participants | Very low |
UVA1 vs narrowband UVB Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs placebo or no treatment Proportion of participants cleared or almost cleared in the short term (10 weeks or 4 months) · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | RR 3.48 [0.82, 14.8] | 2 studies · 40 participants | Very low |
Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · for chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs placebo or no treatment Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs placebo or no treatment Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs placebo or no treatment Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs placebo or no treatment Proportion of participants without relapse in the long term (6 months) · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | RR 2.39 [0.92, 6.17] | 1 study · 26 participants | Very low |
Etretinate vs placebo or no treatment Proportion of participants with adverse effects ‐ measured over 12 weeks · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | RR 3.5 [0.95, 12.9] | 1 study · 20 participants | Very low |
Etretinate vs placebo or no treatment Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy Proportion of participants cleared or almost cleared in the short term (20 weeks) · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | RR 1.91 [1.04, 3.5] | 1 study · 20 participants | Very low |
Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · for chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy Proportion of participants with adverse effects ‐ measured over 20 weeks · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | RR 17 [1.11, 259.87] | 1 study · 20 participants | Very low |
Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs PUVA therapy Proportion of participants cleared or almost cleared in the short term (12 weeks) · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | RR 11.2 [4.16, 30.18] | 1 study · 84 participants | Very low |
Etretinate vs PUVA therapy Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs PUVA therapy Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs PUVA therapy Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs PUVA therapy Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etretinate vs PUVA therapy Proportion of participants with adverse effects ‐ measured over 12 weeks · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | RR 11.54 [5.17, 25.74] | 1 study · 84 participants | Very low |
Etretinate vs PUVA therapy Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream Proportion of participants without relapse in the long term ‐ not reported · for chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Alitretinoin vs placebo Proportion of participants cleared or almost cleared ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Alitretinoin vs placebo Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Alitretinoin vs placebo Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Alitretinoin vs placebo Proportion of participants achieving a 50% reduction in disease severity in the long term (24 weeks) · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | RR 0.69 [0.36, 1.3] | 1 study · 33 participants | Moderate |
Alitretinoin vs placebo Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Alitretinoin vs placebo Proportion of participants with adverse effects ‐ measured over 24 weeks · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | RR 0.84 [0.61, 1.17] | 1 study · 33 participants | Moderate |
Alitretinoin vs placebo Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs placebo Proportion of participants cleared or almost cleared in the short term (3 months) · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | RR 1.64 [0.08, 34.28] | 1 study · 15 participants | Low |
Etanercept vs placebo Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs placebo Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream Proportion of participants with adverse effects ‐ measured over 8 weeks · for chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | 1 study · 19 participants | Very low |
Etanercept vs placebo Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs placebo Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs placebo Proportion of participants with adverse effects ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs placebo Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Ustekinumab vs placebo Proportion of participants cleared or almost cleared ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Ustekinumab vs placebo Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Ustekinumab vs placebo Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Ustekinumab vs placebo Proportion of participants achieving a 50% reduction in disease severity in the short term (16 weeks) · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | RR 0.48 [0.11, 2.13] | 1 study · 33 participants | Low |
Ustekinumab vs placebo Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |